Summary
This 8-K/A filing from Abbott Laboratories (ABT) serves as an amendment to a previous report filed on January 5, 2017. The primary purpose of this amendment is to provide the previously omitted financial disclosures required by Item 9.01 of Form 8-K, specifically concerning the acquisition of St. Jude Medical, Inc. The acquisition was officially completed on January 4, 2017, as per the Agreement and Plan of Merger dated April 27, 2016. Investors should note that this filing includes the audited financial statements of St. Jude Medical, Inc. for the three years ended December 31, 2016, as well as its balance sheets as of December 31, 2016, and January 2, 2016. Additionally, unaudited pro forma condensed combined financial information, including a balance sheet as of December 31, 2016, and a statement of earnings for the year ended December 31, 2016, are provided. These financial details are crucial for understanding the financial impact of the St. Jude Medical acquisition on Abbott's consolidated financial position and performance.
Key Highlights
- 1Abbott Laboratories (ABT) officially completed its acquisition of St. Jude Medical, Inc. on January 4, 2017.
- 2This filing is an amendment (8-K/A) to a previous report and provides essential financial disclosures that were initially omitted.
- 3The filing includes the audited financial statements of St. Jude Medical, Inc. for the three years ending December 31, 2016.
- 4Audited consolidated balance sheets for St. Jude Medical, Inc. as of December 31, 2016, and January 2, 2016, are now included.
- 5Unaudited pro forma condensed combined financial information reflecting the merger is provided as of December 31, 2016, and for the year ended December 31, 2016.
- 6The document incorporates exhibits containing the St. Jude Medical financial statements and the pro forma financial information.
- 7The consent of Ernst & Young LLP, independent auditors for St. Jude Medical, Inc., is also included as an exhibit.